Management of Hyperglycemic Hyperosmolar State in Remission

Protocol for Transitioning from Intravenous to Subcutaneous Insulin

The American Diabetes Association recommends administering subcutaneous basal insulin 2-4 hours before completely stopping the intravenous infusion to prevent rebound hyperglycemia and recurrence of the hyperglycemic hyperosmolar state in patients with a history of this condition 1, 2
Before considering the transition, verify that all of the following criteria are met: glucose <200 mg/dL, patient is alert and able to tolerate oral intake, and there are no signs of shock or severe dehydration 1, 2
The administration of basal insulin (glargine or detemir) subcutaneously 2-4 hours before stopping the intravenous infusion is a critical step, allowing for adequate absorption of the long-acting insulin and preventing rebound hyperglycemia 1, 2, 3
Recent studies demonstrate that adding a low dose of basal insulin analog during the intravenous infusion can prevent rebound hyperglycemia without increasing the risk of hypoglycemia 1, 2

Once the patient is able to eat, initiate a multiple-dose regimen that combines basal insulin (glargine or detemir) once daily, and rapid-acting or short-acting insulin before meals 1, 2, 3
The initial dose of insulin is approximately 0.1-0.2 U/kg/day for patients with mild to moderate hyperglycemia 4

Monitor glucose levels every 2-4 hours during the transition phase to detect rebound hyperglycemia (>200 mg/dL), hypoglycemia (<70 mg/dL), and changes in mental status 1, 2, 3

For patients with persistent severe hyperglycemia, consider a more intensive basal-bolus regimen from the start 4
Monitor potassium levels closely, as hypokalemia occurs in approximately 50% of cases during treatment, and levels <2.5 mEq/L are associated with increased in-hospital mortality 5
Continue the intravenous infusion for 1-2 hours after administering subcutaneous insulin to ensure therapeutic levels of circulating insulin before complete discontinuation 3